This Company Leads The Way In Cannabinoid Treatment Innovation With New Patent
Portfolio Pulse from Jelena Martinovic
SciSparc Ltd. (NASDAQ:SPRC) has been granted a new patent by the European Patent Office, aligning with the company's objective to increase the safety of cannabinoid treatments while maintaining their therapeutic effects. The patent, also granted in the United States, Japan, and Australia, relates to compositions and methods for potentiating therapeutic effects and reducing side effects of selected cannabinoids. Following the announcement, SciSparc's shares traded 37.06% higher at $5.04 per share.
October 03, 2023 | 3:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SciSparc's new patent could potentially increase the safety and efficacy of cannabinoid treatments, which could lead to increased demand for the company's products. This news has already positively impacted the company's stock price.
The new patent granted to SciSparc could potentially increase the safety and efficacy of cannabinoid treatments, which could lead to increased demand for the company's products. This news has already positively impacted the company's stock price, which traded 37.06% higher following the announcement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100